视网膜分支静脉阻塞继发黄斑水肿的治疗进展  

Recent advances in treatment of macular edema secondary to branch retinal vein occlusion

作　　者：明静[1] 谢立科[1] 秦睿[1] MING Jing;XIE Like;QIN Rui(Department of Cataract No.2,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)

机构地区：[1]中国中医科学院眼科医院白内障眼病2科,北京市100040

出　　处：《眼科新进展》2020年第9期879-884,共6页Recent Advances in Ophthalmology

基　　金：北京市中医药科技发展资金项目(编号:JJ2018-95)。

摘　　要：黄斑水肿(macular edema,ME)是视网膜分支静脉阻塞(branch retinal vein occlusion,BRVO)的常见并发症,也是导致视力下降的主要原因。目前,BRVO继发ME的治疗主要包括黄斑格栅样激光光凝和玻璃体内注射激素或抗血管内皮生长因子药物。激素类药物主要包括曲安奈德和地塞米松玻璃体植入剂,抗血管内皮生长因子药物包括雷珠单抗、贝伐单抗、阿柏西普、康柏西普。玻璃体切割术是BRVO继发ME一种有前景的治疗方法。Macular edema is a common complication of branch retinal vein occlusion damaging visual function.At present,the treatment of macular edema secondary to branch retinal vein occlusion mainly includes macular grid-pattern laser photocoagulation and intravitreal injection of glucocorticoids or anti-vascular endothelial growth factor drugs.Glucocorticoids drugs mainly include triamcinolone acetonide and dexamethasone intravitreal implants.Anti-vascular endothelial growth factor drugs include ranibizumab,bevacizumab,aflibercept,and conbercept.In addition,vitrectomy is a promising treatment.

关 键 词：视网膜分支静脉阻塞 黄斑水肿 治疗 

分 类 号：R774.1[医药卫生—眼科]